Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193).
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019731:Carbon-Nitrogen Ligases; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004273:DNA, Neoplasm / Q000096:biosynthesis; D007042:Hypoxanthines / Q000378:metabolism; D007168:IMP Dehydrogenase / Q000378:metabolism; D007939:Leukemia L1210 / Q000188:drug therapy; D007941:Leukemia P388 / Q000188:drug therapy; D008025:Ligases / Q000378:metabolism; D051379:Mice; D012254:Ribavirin / Q000031:analogs & derivatives / Q000494:pharmacology*; D012263:Ribonucleosides / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D007042:Hypoxanthines; D012263:Ribonucleosides; D012254:Ribavirin; D007168:IMP Dehydrogenase; D008025:Ligases; D019731:Carbon-Nitrogen Ligases; C020828:GMP synthase (glutamine-hydrolyzing); C033706:tiazofurin